×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VKTX – viking therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VKTX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/1
07:47 am
vktx
These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target [Yahoo! Finance]
Low
Report
These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target [Yahoo! Finance]
3/31
08:07 am
vktx
2 Healthcare Stocks Wall Street Analysts Say Could Rally 60% or More [Yahoo! Finance]
Medium
Report
2 Healthcare Stocks Wall Street Analysts Say Could Rally 60% or More [Yahoo! Finance]
3/30
08:08 pm
vktx
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors [Yahoo! Finance]
Medium
Report
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors [Yahoo! Finance]
3/30
07:16 am
vktx
Viking Therapeutics (VKTX) Stock Has Failed To Impress Since Jim Cramer Expressed Caution [Yahoo! Finance]
Medium
Report
Viking Therapeutics (VKTX) Stock Has Failed To Impress Since Jim Cramer Expressed Caution [Yahoo! Finance]
3/28
08:08 pm
vktx
A Look At Viking Therapeutics (VKTX) Valuation As VK2735 Phase 3 Enrollment Reaches Completion [Yahoo! Finance]
Medium
Report
A Look At Viking Therapeutics (VKTX) Valuation As VK2735 Phase 3 Enrollment Reaches Completion [Yahoo! Finance]
3/26
10:00 am
vktx
Viking Therapeutics (VKTX) is now covered by Wolfe Research. They set a "peer perform" rating on the stock.
Low
Report
Viking Therapeutics (VKTX) is now covered by Wolfe Research. They set a "peer perform" rating on the stock.
3/26
07:31 am
vktx
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 [Yahoo! Finance]
Low
Report
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 [Yahoo! Finance]
3/26
07:05 am
vktx
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735
Medium
Report
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735
Date
Time
Symbol
Company Name
Action
%Chg
10/22/2025
04:05 pm
VKTX
viking therapeutics, inc.
MISS
Report
8.0%
viking therapeutics, inc.
4/23/2025
04:05 pm
VKTX
viking therapeutics, inc.
MISS
Report
-1.1%
viking therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/1
04:17 pm
vktx
Form ARS Viking Therapeutics, For: Dec 31
Medium
Report
Form ARS Viking Therapeutics, For: Dec 31
4/1
04:16 pm
vktx
Form DEFA14A Viking Therapeutics,
Medium
Report
Form DEFA14A Viking Therapeutics,
4/1
04:15 pm
vktx
Form DEF 14A Viking Therapeutics, For: May 19
Medium
Report
Form DEF 14A Viking Therapeutics, For: May 19
3/27
01:53 pm
vktx
Form SCHEDULE 13G/A Viking Therapeutics, Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A Viking Therapeutics, Filed by: VANGUARD GROUP INC
3/10
06:21 pm
vktx
Form 4 Viking Therapeutics, For: Mar 10 Filed by: Aubuchon Neil William
Low
Report
Form 4 Viking Therapeutics, For: Mar 10 Filed by: Aubuchon Neil William
2/11
05:26 pm
vktx
Form 10-K Viking Therapeutics, For: Dec 31
Low
Report
Form 10-K Viking Therapeutics, For: Dec 31
2/11
04:06 pm
vktx
Form 8-K Viking Therapeutics, For: Feb 11
Medium
Report
Form 8-K Viking Therapeutics, For: Feb 11
1/26
07:57 pm
vktx
Form 4 Viking Therapeutics, For: Jan 12 Filed by: Aubuchon Neil William
Low
Report
Form 4 Viking Therapeutics, For: Jan 12 Filed by: Aubuchon Neil William
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/5
Viking Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
19.0%
3/19 Viking Therapeutics Inc (NASDAQ: VKTX) had its "buy" rating re-affirmed by analysts at William Blair. 8.1%
5/4 Viking Therapeutics Inc (NASDAQ: VKTX) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 7.2%
12/21 Viking Therapeutics Inc (NASDAQ: VKTX) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. 5.8%
4/3 Form 4 Viking Therapeutics, For: Mar 31 Filed by: MORNEAU MICHAEL 5.4%
11/12 Viking Therapeutics to Participate in Upcoming Investor Conferences 4.9%
10/31 Form 4 Viking Therapeutics, For: Oct 31 Filed by: MORNEAU MICHAEL 4.7%
3/17 Form 8-K Viking Therapeutics, For: Mar 17 3.7%
7/15 Viking Therapeutics Inc (NASDAQ: VKTX) is now covered by analysts at Citigroup Inc. They set an "outperform" rating on the stock. 3.5%
8/6 Viking Therapeutics Inc (VKTX) Q2 2019 Earnings Call Transcript [The Motley Fool] 2.6%
3/19 Viking Therapeutics Inc (NASDAQ: VKTX) had its "buy" rating re-affirmed by analysts at William Blair. 8.1%
5/4 Viking Therapeutics Inc (NASDAQ: VKTX) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 7.2%
12/21 Viking Therapeutics Inc (NASDAQ: VKTX) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. 5.8%
4/3 Form 4 Viking Therapeutics, For: Mar 31 Filed by: MORNEAU MICHAEL 5.4%
11/12 Viking Therapeutics to Participate in Upcoming Investor Conferences 4.9%
10/31 Form 4 Viking Therapeutics, For: Oct 31 Filed by: MORNEAU MICHAEL 4.7%
3/17 Form 8-K Viking Therapeutics, For: Mar 17 3.7%
7/15 Viking Therapeutics Inc (NASDAQ: VKTX) is now covered by analysts at Citigroup Inc. They set an "outperform" rating on the stock. 3.5%
8/6 Viking Therapeutics Inc (VKTX) Q2 2019 Earnings Call Transcript [The Motley Fool] 2.6%
TOP News Decliners
11/19
Viking launches mid-stage study of VK2809 in NASH; shares up 7% premarket [Seeking Alpha]
-15.5%
3/21 Viking Therapeutics Inc (NASDAQ: VKTX) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -9.0%
1/3 Form 4 Viking Therapeutics, For: Jan 02 Filed by: SINGLETON J MATTHEW -9.0%
2/26 Form 10-K Viking Therapeutics, For: Dec 31 -8.7%
5/28 Viking Therapeutics to Participate in Upcoming Investor Conferences -8.2%
5/1 Viking Therapeutics Inc (NASDAQ: VKTX) is now covered by analysts at BTIG Research. They set a "buy" rating and a $9.00 price target on the stock. -7.6%
8/11 Is Viking Therapeutics a Buy? [The Motley Fool] -7.3%
8/1 Q2/2019 6/30/2019 EPS -0.110 ZacksConsensus -0.090 ActVsEst (0.020) - Miss -6.6%
5/7 3 Top Biotech Stocks to Buy in May [The Motley Fool] -6.2%
4/14 Viking Therapeutics Inc (NASDAQ: VKTX) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -5.8%
3/21 Viking Therapeutics Inc (NASDAQ: VKTX) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -9.0%
1/3 Form 4 Viking Therapeutics, For: Jan 02 Filed by: SINGLETON J MATTHEW -9.0%
2/26 Form 10-K Viking Therapeutics, For: Dec 31 -8.7%
5/28 Viking Therapeutics to Participate in Upcoming Investor Conferences -8.2%
5/1 Viking Therapeutics Inc (NASDAQ: VKTX) is now covered by analysts at BTIG Research. They set a "buy" rating and a $9.00 price target on the stock. -7.6%
8/11 Is Viking Therapeutics a Buy? [The Motley Fool] -7.3%
8/1 Q2/2019 6/30/2019 EPS -0.110 ZacksConsensus -0.090 ActVsEst (0.020) - Miss -6.6%
5/7 3 Top Biotech Stocks to Buy in May [The Motley Fool] -6.2%
4/14 Viking Therapeutics Inc (NASDAQ: VKTX) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -5.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: